Description: Save the date for SOA's 2022 Health Meeting.

Description: This paper helps the audience understand the actuary’s role in estimating the financial impact of primary care programs. In addition, the paper can be used by actuaries to think about key issues when estimating the financial impact of their employers’ and clients’ own primary care programs.

Description: In this article, the author discusses the insurance market in Switzerland.

Description: Chris Smith, vice chair of the Actuary of the Future section, had the privilege of attending the SOA Health meeting in Seattle for the first time this year. Read about his experience and thoughts on why you should plan to attend an SOA-sponsored conference for your career growth.

Description: “E-Cigarettes: A Hazard or a Help?” by Sam Gutterman was published online in the North American Actuarial Journal on December 18, 2019, and in print in Volume 24, 2020–Issue 4. This essay is the author’s update to the original paper; it has not been peer-reviewed. The essay is solely an expression of the views, opinions, and ideas of the essay author for applying the original research to actuarial work.

Description: The purpose of this document is to inform the user of the 2022 Health Care Cost Model about the sources of data, other reports, and assumptions which were used to populate this report and drive some of the key considerations.

Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: 2002 Valuation Actuary Symposium, Lake Buena Vista, FL. Four key processes are critical to a merger and acquisition transaction: due diligence, negotiation, integration planning and implementation. The panelists discussed how these processes apply to transactions that involve the health area.

Description: This is a discussion about senior citizens' policies and how they compare to other policies. From Transactions of Society of Actuaries 1962, Vol. 14 Pt. 2